Amplimune® Receives US OMRI Listing for Use in Organic Cattle Production
Amplimune®, our immunotherapeutic for calf scours, has received an Organic Materials Review Institute (OMRI) Listing in the U.S.A. This means that Amplimune can be used in compliance with the USDA National Organic Program.
MCWF Shows Promise in Controlling Mycoplasma in Dairy Cattle
NovaVive's MCWF technology has demonstrated potential to control chronic Mycoplasma bovis (M. bovis) infection in dairy cows. M. bovis causes respiratory disease, ear infection, arthritis, mastitis, abortion and other issues.
NovaVive Signs a Co-Operation Agreement with Hoken Biotechnology to Register and Market Amplimune™ in Asia
NovaVive and Hoken Biotechnology have committed to work together to introduce Amplimune™ to Asian markets. Hoken will conduct clinical studies to support regulatory submissions and will be our sales and marketing agent.
NovaVive Presents Data Demonstrating Reduction in Antibiotic Use with MCWF in Young Calves
NovaVive today presented a Research Report at the 2017 ACVIM Forum in National Harbor, Maryland. The report summarized the results of a study conducted in a large Canadian veal operation with Amplimune™.
Antibiotic Alternative for Cattle Now Available to Canadian Veterinarians
Amplimune™ is now available to Canadian veterinarians. Amplimune is an immunomodulator that reduces the clinical signs/mortality associated with E. coli diarrhea in neonatal calves. It offers an alternative to antibiotics.
Antibiotic Alternative for Cattle Approved for Sale in Canada by the Canadian Food Inspection Agency
Amplimune™ has received approval for sale in Canada by the Canadian Food Inspection Agency. The Company believes this is the first antibiotic alternative therapy for livestock to receive Canadian regulatory approval.